Recombinant Alpha-2 Interferon Therapy for Kaposi's Sarcoma Associated with the Acquired Immunodeficiency Syndrome

Publisher Website
Google Scholar
Abstract
In a randomized prospective study the toxicity and efficacy of recombinant .alpha.-2 interferon was tested in the treatment of Kaposi''s sarcoma associated with the acquired immunodeficiency syndrome. High doses L50 .times. 106 U/m2 body surface area, i.v.) or low doses (1 .times. 106 U/m2, s.c.) of recombinant .alpha.-2 interferon were administered to 20 patients for 5 days/wk, every other week, for 4 treatment cycles. Therapy was well tolerated subjectively and caused only mild hematologic and hepatic toxicity at both dose levels. No consistent or sustained changes were seen in immunologic variables during or after treatment. Six patients with Kaposi''s sarcoma, 4 at high dose and 2 at low dose, had objective responses (complete or partial) to treatment. However, therapy did not appear to eradicate cytomegalovirus carriage or prevent opportunistic infections related to cytomegalovirus.

This publication has 4 references indexed in Scilit: